Overexpression of the c-erbB-2 protein in human breast tumor cell lines
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The c‐erbB‐2 proto‐oncogene is amplified in a high percentage of primary human breast tumors, suggesting that the overexpression of this gene may be involved in the development of human breast cancer. We have investigated five human breast tumor cell lines and have detected amplified c‐erbB‐2 gene copies in two of them. This amplification leads to overexpression of the c‐erbB‐2 protein. In addition, two other cell lines have elevated protein levels without gene amplification, suggesting that other mechanisms can lead to overexpression of the c‐erbB‐2 protein. These results are similar to those that we obtained during a study of primary breast tumors (Berger et al.: Cancer Res 48:1238–1243, 1988). These breast tumor cell lines should be useful for an analysis of c‐erbB‐2 expression and of the mechanisms that in some cases lead to overexpression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Analysis of the SK-BR-3 gDNA identified high levels of HER2 amplification that corresponds with the published copy number range (14–24 copies per diploid genome) (41,43–45,47).”
From Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation (2012) · cites this paper as [47]
Citations
Cites
Detection of specific sequences among DNA fragments separated by gel electrophoresis
Southern, E. M. (1975) · Journal of Molecular Biology · doi:10.1016/s0022-2836(75)80083-0 · Cited by 32,249
Hsu, S. M., Raine, L., & Fanger, H. (1981) · Journal of Histochemistry & Cytochemistry · doi:10.1177/29.4.6166661 · Cited by 14,140
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Carpenter, G., & Cohen, S. (1979) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.48.070179.001205 · Cited by 2,909
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Ribonucleic acid isolated by cesium chloride centrifugation
Glisin, V., Crkvenjakov, R., & Byus, C. (1974) · Biochemistry · doi:10.1021/bi00709a025 · Cited by 2,156
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
The Molecular Genetics of Cancer
Bishop, J. M. (1987) · Science · doi:10.1126/science.3541204 · Cited by 1,688
Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito, T., & Toyoshima, K. (1986) · Nature · doi:10.1038/319230a0 · Cited by 1,204
Research works printed but not linked: 2
- Berger MS, 1988, Cancer Res, 48, 1238
- Redmond SMS, 1988, Oncogene, 2, 259
Cited by
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
“21N (Hynes et al., 1989), ErbB-3-specific affinity purified rabbit polyHowever, the presence of ErbB-2 dramatically enhances clonal antibody C17 (Santa Cruz Biotechnology), ErbB-4-specific mAb transactivation of NDF receptors by ErbB-1, demonstrating 111 (Chen et al., 1996), ErbB-4-specific…”
BackgroundSelf-citationSeidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L., Kaptain, S., Bach, A., Panageas, K. S., Arroyo, C., Valero, V., Currie, V., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2587 · Cited by 547
Pegram, M. D., Konecny, G. E., O'Callaghan, C., Beryt, M., Pietras, R., & Slamon, D. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh131 · Cited by 512
“Multiple drug effect analysis was performed using four HER2-overexpressing cell lines ( 23 ,24).”
MethodDifferential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
“Amplification and overexpression of HER2 are found frequently in breast-tumor-derived cell lines [25, 30, 31] and in human mammary carcinomas [6, 61-63].”
BackgroundWhale, A. S., Huggett, J. F., Cowen, S., Speirs, V., Shaw, J., Ellison, S., Foy, C. A., & Scott, D. J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks203 · Cited by 453
ErbB Receptor-induced Activation of Stat Transcription Factors Is Mediated by Src Tyrosine Kinases
Olayioye, M. A., Beuvink, I., Horsch, K., Daly, J. M., & Hynes, N. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17209 · Cited by 367
Self-citationPositive and negative regulation of endogenous genes by designed transcription factors
Beerli, R. R., Dreier, B., & Barbas, C. F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040552697 · Cited by 305
Beerli, R. R., & Hynes, N. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.11.6071 · Cited by 308
Self-citationWaibel, R., Alberto, R., Willuda, J., Finnern, R., Schibli, R., Stichelberger, A., Egli, A., Abram, U., Mach, J.-P., Plückthun, A., et al. (1999) · Nature Biotechnology · doi:10.1038/12890 · Cited by 303
Graus-Porta, D., Beerli, R. R., & Hynes, N. E. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.3.1182 · Cited by 296
“5 mg of total protein with, respectively, MAb EGFR1, antiserum 21N (28), and rabbit polyclonal antibody C17.”
BackgroundMethodInfluentialSelf-citation(2001) · PubMed · Cited by 270
ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner
Olayioye, M. A., Graus-Porta, D., Beerli, R. R., Rohrer, J., Gay, B., & Hynes, N. E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.9.5042 · Cited by 262
“ErbB-2-specific MAb FRP5 (24) and polyclonal rabbit antiserum 21N (28);”
BackgroundSelf-citationReal-Time Reverse Transcription-PCR Assay for Future Management of ERBB2-based Clinical Applications
Bièche, I., Onody, P., Laurendeau, I., Olivi, M., Vidaud, D., Lidereau, R., & Vidaud, M. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.8.1148 · Cited by 254
c-Src, Receptor Tyrosine Kinases, and Human Cancer
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60774-5 · Cited by 243
Bosher, J. M., Williams, T., & Hurst, H. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.3.744 · Cited by 229
Blancher, C., Moore, J. W., Talks, K., Houlbrook, S., & Harris, A. L. (2000) · PubMed · Cited by 255
Lafky, J. M., Wilken, J. A., Baron, A. T., & Maihle, N. J. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.01.001 · Cited by 215
Wels, W. S., Harwerth, I. M., Mueller, M., Groner, B., & Ne, H. (1992) · PubMed · Cited by 186
Self-citationBeerli, R. R., Graus-Porta, D., Woods-Cook, K., Chen, X., Yarden, Y., & Hynes, N. E. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6496 · Cited by 182
“The antibodies used were ErbB-2-specific antiserum 21N (25) and monoclonal antibody (MAb)”
BackgroundSelf-citationSharma, A., Koldovsky, U., Xu, S., Mick, R., Roses, R., Fitzpatrick, E., Weinstein, S., Nisenbaum, H., Levine, B. L., Fox, K., et al. (2012) · Cancer · doi:10.1002/cncr.26734 · Cited by 164
Targeting HER2 in other tumor types
Scholl, S., Beuzeboc, P., & Pouillart, P. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s81 · Cited by 164
Expression of the c-erbB-2 (Her-2/neu) Oncoprotein in Human Prostatic Carcinoma
Kuhn, E. J., Kurnot, R. A., Sesterhenn, I. A., Chang, E. H., & Moul, J. W. (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)35799-3 · Cited by 158
Intracellular expression of single chain antibodies reverts ErbB-2 transformation.
Beerli, R. R., Wels, W., & Hynes, N. E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)51027-4 · Cited by 155
Self-citationMénard, S., Casalini, P., Campiglio, M., Pupa, S. M., Agresti, R., & Tagliabue, E. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s15 · Cited by 149
Toward Selection of Internalizing Antibodies from Phage Libraries
Becerril, B., Poul, M., & Marks, J. D. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0177 · Cited by 158
Hollywood, D. P., & Hurst, H. C. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05891.x · Cited by 136
Hynes, N. E., Taverna, D., Harwerth, I. M., Ciardiello, F., Salomon, D. S., Yamamoto, T. S., & Groner, B. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.8.4027-4034.1990 · Cited by 127
Self-citationWels, W. S., Harwerth, I. M., Zwickl, M., Hardman, N., Groner, B., & Hynes, N. E. (1992) · Nature Biotechnology · doi:10.1038/nbt1092-1128 · Cited by 123
Self-citationHarwerth, I. M., Wels, W., Marte, B. M., & Hynes, N. E. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42160-6 · Cited by 122
Self-citationDaly, J. M., Jannot, C. B., Beerli, R. R., Graus-Porta, D., Maurer, F. G., & Hynes, N. E. (1997) · PubMed · Cited by 115
Self-citationHigh-level expression of the ribosomal protein L19 in human breast tumors that overexpress erbB-2.
Henry, J. L., Coggin, D. L., & Cr, K. (1993) · PubMed · Cited by 113
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
Harwerth, I. M., Wels, W. S., Schlegel, J., Müller, M., & Ne, H. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.494 · Cited by 114
“The erbB-2 protein was immunoprecipitated from aliquots of lysate containing equal amounts of [35S] using the 21N antiserum (Hynes et al., 1989).”
BackgroundMethodAmplification and differential expression of members of theerbB-gene family in human glioblastoma
Schlegel, J., Stumm, G., Br�ndle, K., Merdes, A., Mechtersheimer, G., Hynes, N. E., & Kiessling, M. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01052920 · Cited by 112
“mors and control specimens was performed as previously described [ 22 ].”
Self-citationAssessment of HER2 status in breast cancer
Dowsett, M., Cooke, T., Ellis, I. O., Gullick, W., Gusterson, B. A., Mallon, E., & Walker, R. A. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00264-6 · Cited by 107
Homann, N., Tillonen, J., & Salaspuro, M. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000415)86:2<169::aid-ijc4>3.0.co;2-3 · Cited by 140
Self-citationWels, W., Beerli, R., Hellmann, P., Schmidt, M., Marte, B. M., Kornilova, E. S., Hekele, A., Mendelsohn, J., Groner, B., & Hynes, N. E. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910600120 · Cited by 97
Self-citationBuchdunger, E., Trinks, U. P., Mett, H., Regenass, U., Müller, M., Meyer, T., McGlynn, E., Pinna, L. A., Traxler, P. M., & Lydon, N. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2334 · Cited by 97
RetractedOppenheimer, C. W., Blalock, W. L., Steelman, L. S., Chang, F., & McCubrey, J. A. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00085-1 · Cited by 100
Molecular and cellular biology of prostate cancer
Lalani, E., Laniado, M., & Abel, P. D. (1997) · Cancer and Metastasis Reviews · doi:10.1023/a:1005792206377 · Cited by 104
Grebenik, E. A., Nadort, A., Generalova, A. N., Нечаев, А. В., Sreenivasan, V. K. A., Khaydukov, E. V., Semchishen, V. A., Popov, A., Sokolov, V. I., Akhmanov, A. S., et al. (2013) · Journal of Biomedical Optics · doi:10.1117/1.jbo.18.7.076004 · Cited by 90
“Experimental confirmation of the bioconjugation reaction and the functionality of the UCNP-Bs:Bn-scFv4D5 biocomplexes was performed by specific immobilization of these biocomplexes on cancer cells, more specifically, human breast adenocarcinoma cells SK-BR-3 known to overexpress HER2/neu, and fixed in 1% paraformaldeh…”
MethodDaly, J. M., Olayioye, M. A., Wong, A. M.-L., Neve, R. M., Lane, H. A., Maurer, F. G., & Hynes, N. E. (1999) · Oncogene · doi:10.1038/sj.onc.1202700 · Cited by 101
“Antibodies used were: ErbB2 speci®c 21N polyclonal antiserum (Hynes et al., 1989), ErbB3 speci®c a nity-puri®ed polyclonal antiserum C17 (Santa Cruz Biotechnology), phosphotyrosine-speci®c mAb, p85-speci®c antiserum (UBI), c-Src speci®c Ab-1 mAb (Calbiochem), anti-phospho-speci®c p38a and p38b/b2…”
Self-citationScott, G. K., Daniel, J. C., Xiong, X., Maki, R. A., Kabat, D., & Benz, C. C. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32098-7 · Cited by 87
Sini, P., Wyder, L., Schnell, C., O’Reilly, T., Littlewood, A., Brandt, R., Hynes, N. E., & Wood, J. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1954 · Cited by 87
Self-citationSaxena, R., & Dwivedi, A. (2010) · Medicinal Research Reviews · doi:10.1002/med.20209 · Cited by 101
“Trastuzumab HER-2 overexpression is seen in 15–30% of breast cancers and is usually caused by gene amplification.(142,143) It is linked to higher grade and extensive forms of ductal carcinoma in situ(144,145) and is also associated with adverse outcome in invasive lobular carcinoma.”
BackgroundMoróte, J., de Torres, I. M., Càceres, C., Vallejo, C. T., Schwartz, S., & Reventós, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990820)84:4<339::aid-ijc1>3.0.co;2-2 · Cited by 84
Gelmini, S., Orlando, C., Sestini, R., Vona, G., Pinzani, P., Ruocco, L., & Pazzagli, M. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.5.752 · Cited by 79
“3 cell line carrying an 11-fold c-erbB-2 amplification [24].”
BackgroundHardell, L., Ohlson, C., & Fredrikson, M. G. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971210)73:6<875::aid-ijc19>3.0.co;2-3 · Cited by 67
Schneider, B., Münkel, S., Krippner‐Heidenreich, A., Grunwald, I., Wels, W. S., Wajant, H., Pfizenmaier, K., & Gerspach, J. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.45 · Cited by 82
“ErbB2 expression analysis confirmed a median versus low expression level for Colo205 colon carcinoma and HT1080 fibrosarcoma cells, respectively (Figure 2a), compared with SKBR3 cells that are well-known to highly express the ErbB2 protein (data not shown).(22) Incubation of Colo205 and HT1080 cells with the fusion pr…”
ResultAntibody internalization studied using a novel IgG binding toxin fusion
Mazor, Y., Barnea, I., Keydar, I., & Benhar, I. (2007) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.01.008 · Cited by 66
Königshoff, M., Wilhelm, J., Bohle, R. M., Pingoud, A., & Hahn, M. (2003) · Clinical Chemistry · doi:10.1373/49.2.219 · Cited by 63
Copine-III interacts with ErbB2 and promotes tumor cell migration
Heinrich, C., Keller, C., Boulay, A., Vecchi, M., Bianchi, M., Sack, R., Lienhard, S., Duss, S., Hofsteenge, J., & Hynes, N. E. (2009) · Oncogene · doi:10.1038/onc.2009.456 · Cited by 65
Self-citationEffect of caffeine and/or cigarette smoking on resting energy expenditure.
Collins, L. C., Cornelius, M., Vogel, R. L., Walker, J. F., & Stamford, B. A. (1994) · PubMed · Cited by 61
Current perspective – Trastuzumab
Hall, P. S., & Cameron, D. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.013 · Cited by 58
A new human antitumor immunoreagent specific for ErbB2.
Lorenzo, C. D., Palmer, D. B., Piccoli, R., Ritter, M. A., & D’Alessio, G. (2002) · PubMed · Cited by 57
An Essential Role for Src Kinase in ErbB Receptor Signaling through the MAPK Pathway
Olayioye, M. A., Badache, A., Daly, J. M., & Hynes, N. E. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5242 · Cited by 57
Self-citationLyon, E., Millson, A., Lowery, M. C., Woods, R., & Wittwer, C. T. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.5.844 · Cited by 54
“The gene dose was then compared with reported values for the cell lines (12, 28, 29).”
ResultAnti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer
Leonard, D. S., Hill, A. D. K., Kelly, L., Dijkstra, B., McDermott, E. W. M., & O’Higgins, N. J. (2002) · British journal of surgery · doi:10.1046/j.0007-1323.2001.02022.x · Cited by 54
Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells.
Marth, C., Müller‐Holzner, E., Greiter, E., Cronauer, M. V., Zeimet, A., Doppler, W., Eibl, B., Hynes, N. E., & Daxenbichler, G. (1990) · PubMed · Cited by 54
Self-citationMillson, A., Suli, A., Hartung, L., Kunitake, S., Bennett, A., Nordberg, M. C. L., Hanna, W., Wittwer, C. T., Seth, A., & Lyon, E. (2003) · The Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60471-0 · Cited by 51
Effects of paclitaxel on cultured synovial cells from patients with rheumatoid arthritis
Kurose, A., Yoshida, W., Yoshida, M., & Sawai, T. (2001) · Cytometry · doi:10.1002/1097-0320(20010801)44:4<309::aid-cyto1122>3.0.co;2-3 · Cited by 24
Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry
Singleton, T. P., Niehans, G. A., Feng, G., Litz, C. E., Hagen, K., Qiu, Q., Kiang, D. T., & Strickler, J. G. (1992) · Human Pathology · doi:10.1016/0046-8177(92)90032-x · Cited by 52
Grunt, T., Dittrich, E., Offterdinger, M., Schneider, S., Dittrich, C., & Huber, H. P. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.446 · Cited by 51
Targeted inhibition of tumor‐cell growth by recombinant heregulin‐toxin fusion proteins
Jeschke, M., Wels, W. S., Dengler, W. A., Imber, R., Stöcklin, E., & Groner, B. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910600527 · Cited by 48
Self-citationDillon, R. L., Brown, S. T., Ling, C., Shioda, T., & Muller, W. J. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00866-07 · Cited by 45
“In addition, ErbB2overexpressing human breast cancer cell lines have been demonstrated to have higher erbB2 transcript levels per gene copy number compared to cell lines expressing low levels of ErbB2 (20, 26).”
BackgroundSestini, R., Orlando, C., Zentilin, L., Lami, D., Gelmini, S., Pinzani, P., Giacca, M., & Pazzagli, M. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.6.826 · Cited by 44
Bera, T. K., Viner, J. L., Brinkmann, E., & Pastan, I. (1999) · PubMed · Cited by 39
Taverna, D., Antoniotti, S., Maggiora, P., Dati, C., Bortoli, M. D., & Hynes, N. E. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910560411 · Cited by 39
Self-citationTargeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response
Lazaro, G., Smith, C. R., Goddard, L., Jordan, N., McClelland, R. A., Barrett-Lee, P. J., Nicholson, R. I., & Hiscox, S. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0019 · Cited by 38
“Cell lines and cell culture Two human breast carcinoma cell lines that constitutively overexpress HER2 because of the amplification of the HER2 gene (BT-474 and MDA-MB-361 (Hynes et al. 1989)) and two human breast carcinoma cells that lack HER2 overexpression (MCF7 and T47D) were obtained from the American Type Cultur…”
MethodDynamic chromatin remodeling on the HER2 promoter in human breast cancer cells
Mishra, S. K., Mandal, M., Mazumdar, A., & Kumar, R. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02951-9 · Cited by 37
Sestini, R., Orlando, C., Zentilin, L., Gelmini, S., Pinzani, P., Bianchi, S., Selli, C., Giacca, M., & Pazzagli, M. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.4.630 · Cited by 35
“Accuracy. To test the accuracy of this method in de. tecting variable degrees of c-erbB-2 gene amplification, we used competitive PCR to measure the number of copies of the oncogene in four human breast cancer cell lines (SKBR-3, ZR75.1, T47D, MDA.MB.231), for which different values of amplification had been reported…”
MethodInfluentialc-erbB-2 protein expression in node negative breast cancer
Richner, J., Gerber, H., Locher, G. W., Goldhirsch, A., Gelber, R. D., Gullick, W. J., Berger, M. S., Groner, B., & Hynes, N. E. (1990) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057745 · Cited by 35
Self-citationNishimura, R., Okumura, Y., & Arima, N. (2007) · Breast Cancer · doi:10.1007/s12282-007-0014-z · Cited by 34
“In the early stage of breast cancer, there is increased expression of the HER2 gene [4, 5], and expression of HER2 receptors on the cell surface is enhanced [ 6 , 7], producing various effects that contribute to the proliferation of cancer cells.”
BackgroundAntoniotti, S., Taverna, D., Maggiora, P., SAPEI, M. L., Hynes, N. E., & Bortoli, M. D. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.454 · Cited by 32
“…the amount of erbB-2 mRNA or pl85erbB-2 measured in some primary tumours and breast cancer cell lines does not directly reflect erbB-2 gene copy number (Kraus et al., 1988; Hynes et al., 1989; King et al., 1989; Dati et al., 1991), implying the existence of mechanisms regulating erbB-2 expression.”
BackgroundSelf-citationHoffman, R. M., Burns, W. W., & Paper, D. H. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00689050 · Cited by 31
“Many tumour cells respond mitogenically to heparin-binding growth factors; examples include glioma cells stimulated by b F G F and P D G F [8, 9], prostate cancer cells stimulated by b F G F [10], breast cancer lines stimulated by pleiotrophin [11] and breast cancer lines and lung carcinoma stimulated by the heparin-b…”
BackgroundAn, H., Niederacher, D., Beckmann, M. W., Göhring, U.-J., Scharl, A. J., Picard, F., van Roeyen, C. R. C., Schnürch, H.-G., & Bender, H. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640502 · Cited by 30
Inhibition of erbB-2-Positive Breast Cancer Cell Growth by erbB-2 Antisense Oligonucleotides
LIU, X., & Pogo, B. G. T. (1996) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1996.6.9 · Cited by 28
“Data represent mean value of two experiments with variation less than 15%. but 10-fold less than the overexpressing cell lines SK-BR3 and BT474 (Kraus et al., 1987; Hynes et al., 1989).”
Molecular Chemotherapy for Breast Cancer
Patterson, A. V., & Harris, A. L. (1999) · Drugs & Aging · doi:10.2165/00002512-199914020-00001 · Cited by 28
Expression of the c-erbB-2-encoded oncoprotein and progesterone receptor in human meningiomas
Schlegel, J., Ullrich, B., Stumm, G., Gass, P., Harwerth, I. M., Hynes, N., & Kiessling, M. (1993) · Acta Neuropathologica · doi:10.1007/bf00228582 · Cited by 26
“Further, brain metastases from 2 breast cancers and 2 ovarian cancers, the breast cancer cell line SK-BR-3 known to contain a ten fold amplification and overproduction of c-erbB-2 [13] and 1 biopsy specimen of nonneoplastic renal tissue were included in the study.”
MethodSelf-citationRetinoids Control the Expression of c-erbB Receptors in Breast Cancer Cells
Offterdinger, M., Schneider, S. M., Huber, H. P., & Grunt, T. W. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9570 · Cited by 26
Dawkins, H. J. S., Robbins, P., Smith, K. L., Sarna, M. K., Harvey, J. M., Sterrett, G. F., & Papadimitriou, J. M. (1993) · Pathology - Research and Practice · doi:10.1016/s0344-0338(11)80853-8 · Cited by 26
Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?
Turner, N. H., Pestrin, M., Galardi, F., Luca, F. D., Malorni, L., & Leo, A. D. (2014) · Cancers · doi:10.3390/cancers6020684 · Cited by 24
“HER2 positivity is a known poor prognostic factor [57–59] with HER2 + breast cancers typified by aggressive clinical course and early relapse.”
BackgroundProposed treatment guidelines for HER2-positive metastatic breast cancer in Europe
Piccart, M. J. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s89 · Cited by 22
Regulation of MUC1 Expression in Human Mammary Cell Lines by the c-ErbB2 and Ras Signaling Pathways
Scibetta, A. G., Albanese, I., Morris, J. R., Cooper, L., Downward, J., Pitha-Rowe, P. M., & Taylor‐Papadimitriou, J. (2001) · DNA and Cell Biology · doi:10.1089/104454901750232463 · Cited by 20
“Of these, the SKBr3 line is known to express high levels of c-ErbB2 (Hynes et al. , 1989; D’Souza et al. , 1993), and the MUC1 promoter construct showed no activity when transfected into SKBr3 (data not shown).”
Cattaneo, M., Lotti, L. V., Martino, S., Alessio, M., Conti, A., Bachi, A., Mariani‐Costantini, R., & Biunno, I. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017206 · Cited by 20
“While p38 resulted expressed in all the tested cell lines, with higher levels in the cancer lines, p28 was detected only in the poorly differentiated metastatic breast cancer line SKBr3 [44].”
Flicker, S., Schneider, S. M., Offterdinger, M., Dittrich, E., Fazeny, B., Valenta, R., Huber, H. P., Dittrich, C., & Grunt, T. W. (1997) · Cancer Letters · doi:10.1016/s0304-3835(97)04715-0 · Cited by 18
Her2 Testing recommendations in Australia
Bilous, M., Ades, C. J., Armes, J. E., Bell, R. H., Brown, R., Cook, B., Cummings, M. C., Field, A. S., Llewellyn, H. R. H., McKenzie, P. R., et al. (2001) · Pathology · doi:10.1080/00313020120083133 · Cited by 17
Wells, V. E., & Mallucci, L. (2009) · Breast Cancer Research · doi:10.1186/bcr2217 · Cited by 18
“activity and akt gene suppression To determine whether GBP could overcome the strength of endogenous mitogenic signalling in aggressive cancers we examined BT474 and SKBR3 breast cancer cells that express high levels of ErbB2 [ 33 ].”
BackgroundSpheroids of HER2-Positive Breast Adenocarcinoma for Studying Anticancer Immunotoxins In Vitro
Balalaeva, I. V., Соколова, Е. А., Puzhikhina, A. D., Brilkina, A. A., & Deyev, S. M. (2017) · Acta Naturae · doi:10.32607/20758251-2017-9-1-38-43 · Cited by 12
HER2/neu: A Target for Breast Cancer Therapy
Zwick, E., Wallasch, C., & Ullrich, A. (2000) · Breast Disease · doi:10.3233/bd-1999-11102 · Cited by 11
“Since in some tumors elevated levels of HER2 protein did not correlate with gene amplification [75,76], it is likely that in these cases overexpression is caused by transcriptional and/or post-transcriptional mechanisms.”
Fluorescent IgG fusion proteins made inE. coli
Luria, Y., Raichlin, D., & Benhar, I. (2012) · mAbs · doi:10.4161/mabs.19581 · Cited by 10
“5 × 10(6) ErbB2 receptors per cell, respectively.(14,15) As shown in Figure 3, the fluorescence intensity obtained with the SFGFP-fused antibodies was in each case almost identical to the fluorescence intensity obtained with the parent Inclonal FRP5 on both cell lines.”
ResultAnalysis of CerbB2 protein content of human glioma cells and tumor tissue
Engelhard, H. H., Wolters, M., & Criswell, P. S. (1995) · Journal of Neuro-Oncology · doi:10.1007/bf01058457 · Cited by 10
“Involvement of the c-erbB2 gene in at least some human malignancies has been suggested by the fact that it is amplified and/or overexpressed in malignant cell lines and tumor specimens [1, 3,15, 22-27].”
BackgroundDissecting the molecular mechanisms of cancer through bioinformatics‐based experimental approaches
Rivenbark, A. G., & Coleman, W. B. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21283 · Cited by 9
“Additional examples of gene amplification can be found for specific cancers, including Her2 amplification in breast cancer [Hynes et al., 1989; Slamon et al., 1989].”
BackgroundChromosome aberrations and oncogene alterations in two new breast tumor cell lines
Sasi, R., Hoo, J. J., Samuel, I., Tainaka, T., Shiferaw, S., & Lin, C. C. (1991) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(91)90137-j · Cited by 9
Turowec, J. P., Lau, E. W. T., Wang, X., Brown, K. R., Fellouse, F. A., Jawanda, K. K., Pan, J., Moffat, J., & Sidhu, S. S. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004420 · Cited by 9
“In SKBR3 cells, which exhibit HER2-amplification and high HER3 levels (38, 39), we found that NRG1 stimulation resulted in robust phosphorylation of HER3 when pretreated with or without an isotype control (Fig.”
BackgroundThe Development of Herceptin®: Paving the Way for Individualized Cancer Therapy
Gutjahr, T., & Reinhardt, C. (2005) · Wiley eBooks · doi:10.1002/9783527620982.ch5 · Cited by 6
Targeted Tumor Cytotoxicity Mediated by Intracellular Single-Chain Anti-oncogene Antibodies
Curiel, D. T. (1997) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60137-4 · Cited by 6
Guvakova, M. A. (2023) · JCO Clinical Cancer Informatics · doi:10.1200/cci.23.00013 · Cited by 5
“13,15,16 In this article, we propose that the probabilistic multiclass classi fi cation on the basis of the continuum of the ERBB2 messenger ’ s expression data may provide insights into the molecular identity of HER2-low.”
Complexes of magnetic nanoparticles and scFv antibodies for targeting and visualizing cancer cells
Shipunova, V. O., Nikitin, M. P., Mironova, K. E., Deyev, S. M., & Nikitin, P. I. (2015) · IEEE International Conference on Nanotechnology (IEEE-NANO) · doi:10.1109/nano.2015.7388956 · Cited by 4
“This cell line is known to overexpress HER2/neu in the amount of ~10(6) receptors per cell, while in normal cells the expression does not exceed 10(3)–10(4) receptors per cell and may be absent at all [17].”
BackgroundSchmidt, M., & Wels, W. S. (2001) · International Journal of Cancer · doi:10.1002/ijc.1618 · Cited by 4
Lyon, E., Millson, A., & Suli, A. (2001) · Springer eBooks · doi:10.1007/978-3-642-59524-0_23 · Cited by 4
Metadata
- Authors
- Hynes, N. E., Gerber, H. A., Saurer, S., & Groner, B.
- Affiliations
- University Hospital of Bern (CH)
- University of Bern (CH)
- ORCID
- Hynes, Nancy E.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 1989-02
- Volume
- 39
- Issue
- 2
- Pages
- 167-173
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W2060531515
- Cited by
- 109
- References
- 28
- Citations by year
- 2026: 1 · 2023: 1 · 2018: 1 · 2017: 2 · 2015: 1 · 2014: 2 · 2013: 2 · 2012: 3
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Cellular Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- c-erbB-2, HER2/neu, gene amplification, protein overexpression, breast cancer, breast cancer cell lines, proto-oncogenes
- MeSH terms
- Proto-Oncogene Mas, Breast Neoplasms, DNA, Neoplasm, Gene Amplification, Nucleic Acid Hybridization, Proto-Oncogene Proteins, RNA, Neoplasm, Tumor Cells, Cultured, Blotting, Southern, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.